Although February coincided with the Lunar New Year holiday and a seasonal slowdown in market activity, global biopharma business development remained highly active. From RNAi licensing and CAR-T acquisitions to antibody collaborations and AI-driven drug discovery alliances, multiple headline transactions were announced in rapid succession, many reaching multi-billion-dollar values.
DIMA BIOTECH will showcase its DiMPro™ Nanodisc-based full-length multi-transmembrane protein solutions and therapeutic antibody discovery platforms at BIOCHINA 2026. With a library of 5,000+ monoclonal antibodies covering 500+ targets and functionally validated GPCR products, we provide exclusive exhibition support to accelerate innovative drug preclinical development.
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, innovative therapies targeting CCR8 showed a strong surge. LM-108 from LaiSun Pharma/China National Biotec Group and ICP-B05 from Innocare demonstrated promising efficacy, with significant depletion of tumor-infiltrating Treg cells. Meanwhile, major pharmaceutical companies including Bristol Myers Squibb, Agenus, Gilead, and Jounce have made substantial investments in CCR8 programs, highlighting the strategic importance of CCR8 as a key target for overcoming resistance to PD-1/L1 therapies.
In this review, we present an integrated overview of TREM2, covering its structure, expression patterns, biological functions, disease relevance, and the current landscape of TREM2-targeted drug development, with the aim of clarifying its potential as an emerging therapeutic target.
STAB1 (Stabilin-1) is an emerging immunoregulatory receptor expressed on tumor-associated macrophages. Targeting STAB1-driven macrophage reprogramming offers a promising strategy to reverse tumor immune suppression and enhance cancer immunotherapy responses within the tumor microenvironment.
January 2026 global pharma BD and M&A activity highlights sustained capital concentration in innovative targets, AI-driven drug discovery, bispecific antibodies, and peptide therapeutics. Large multinational pharmaceutical companies continue to rapidly reinforce pipelines through acquisitions, licensing, and strategic collaborations, while Chinese innovators steadily enhance their negotiating power on the global stage.
Membrane proteins are critical drug targets, but their hydrophobic and structurally complex nature has limited antibody discovery. Nanodisc technology stabilizes membrane proteins in a lipid-like environment, preserving native conformations and enabling effective antibody immunization and screening.
Over the past year, Cadherin-3 (CDH3, P-cadherin), traditionally regarded as a classical cell-cell adhesion molecule, has increasingly attracted attention in oncology drug development and international scientific conferences. Early clinical data from CDH3-targeted antibody drug conjugates (ADCs) in solid tumors, particularly non-small cell lung cancer (NSCLC), have demonstrated promising objective response signals, drawing significant interest from both academia and the biopharmaceutical industry. In parallel, bispecific antibodies and T cell redirection strategies targeting CDH3 have entered early clinical or translational exploration. Collectively, these advances suggest that CDH3 is transitioning from a tumor-associated marker to a therapeutically actionable cancer target with translational potential.
Cadherin-17 (CDH17) is a non-classical calcium-dependent adhesion protein predominantly expressed in the intestinal epithelium and highly upregulated in multiple gastrointestinal tumors. Due to its tumor-specific expression, CDH17 has become a promising therapeutic target. Current CDH17-targeting strategies include: Antibody-drug conjugates (ADC), Cell therapies (CAR-T/CAR-NK), Monoclonal, bispecific, or trispecific antibodies.
The thyroid-stimulating hormone receptor (TSHR) has re-emerged as a key target in endocrinology and autoimmune disease research. Therapeutic strategies targeting TSHR have expanded rapidly, encompassing blocking monoclonal antibodies, small-molecule antagonists, and novel approaches to modulate pathogenic autoantibodies. Clinical studies demonstrate encouraging safety and early efficacy of TSHR-directed antibodies in Graves’ disease and thyroid eye disease, while orally available antagonists and inverse agonists offer new options for long-term treatment. Importantly, recent findings extend the role of TSHR beyond hyperthyroidism to immunometabolic regulation and thyroid cancer, positioning TSHR as a multidimensional therapeutic target across immunity, metabolism, and oncology.